Astria TherapeuticsATXS
ATXS
About: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Employees: 59
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
20% more capital invested
Capital invested by funds: $518M [Q2] → $622M (+$105M) [Q3]
3% more funds holding
Funds holding: 100 [Q2] → 103 (+3) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
3.38% less ownership
Funds ownership: 103.6% [Q2] → 100.22% (-3.38%) [Q3]
15% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 39
37% less call options, than puts
Call options by funds: $482K | Put options by funds: $769K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
104%
upside
Avg. target
$23
197%
upside
High target
$28
256%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Jonathan Wolleben 38% 1-year accuracy 28 / 74 met price target | 231%upside $26 | Market Outperform Initiated | 31 Jan 2025 |
HC Wainwright & Co. Joseph Pantginis 26% 1-year accuracy 104 / 406 met price target | 104%upside $16 | Buy Reiterated | 23 Jan 2025 |
Oppenheimer Hartaj Singh 24% 1-year accuracy 6 / 25 met price target | 256%upside $28 | Outperform Maintained | 14 Nov 2024 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced initiation of a Phase 1a clinical trial of STAR-0310 in healthy subjects. STAR-0310, a high affinity monoclonal antibody OX40 antagonist that incorporates YTE technology, is in development for the potential treatment of atopic dermatitis (AD) and potentially other indications. The Phase 1a trial is inte.
Neutral
Business Wire
2 weeks ago
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced its planned design of the ALPHA-ORBIT Phase 3 clinical trial of navenibart in people with hereditary angioedema (HAE), which will include both every 3- (Q3M) and every 6-month (Q6M) treatment arms with the primary analysis at 6 months. Global start-up activities are underway, and ALPHA-ORBIT is expected.
Neutral
Business Wire
4 weeks ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650 shares of Astria's common stock on January 2, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were gran.
Positive
Zacks Investment Research
1 month ago
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?
Here is how Astria Therapeutics, Inc. (ATXS) and Abbott (ABT) have performed compared to their sector so far this year.
Neutral
Business Wire
1 month ago
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive final results from the target enrollment group of 16 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These final results demonstrated reduction in the mean mont.
Neutral
Business Wire
1 month ago
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for STAR-0310, a monoclonal antibody OX40 antagonist, the company is developing as a potential treatment for atopic dermatitis (AD) and potentially other indications. A Phase 1a trial of STAR-0310 in.
Neutral
Business Wire
2 months ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 32,500 shares of Astria's common stock on December 2, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were gra.
Positive
Seeking Alpha
2 months ago
Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema
Astria Therapeutics, Inc.'s STAR-0215 shows 90-96% reduction in HAE attack frequency, with a twice-a-year dosing regimen, positioning it as a transformative therapy. The company has a strong cash balance of $344 million, ensuring a runway until 2027, supporting continued development and trials. Competitive positioning is strong, with STAR-0215 outperforming existing treatments like Takhzyro and Haegarda in both efficacy and dosing convenience.
Neutral
Business Wire
2 months ago
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “We had another strong quarter of execution for both navenibart and STAR-0310,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. “We are excited about the opportunity for navenibar.
Neutral
Business Wire
2 months ago
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on Wednesday, November 20th at 12:00pm GMT in London, UK. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff315/at.
Charts implemented using Lightweight Charts™